Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intra-lesional MMR Immunotherapy for Recalcitrant Tinea Cruris and Corporis
NCT07312604Recruiting
- Start
- Dec 2025
- Primary completion
- Mar 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of measles, mumps and rubella vaccine (live) in tinea corporis and Tinea cruris (TC). Primary endpoint: Percent reduction in affected body surface area at 12 weeks. Started Dec 2025; status: recruiting.
02
Drugs
measles, mumps and rubella vaccine (live)
03
Conditions
tinea corporisTinea cruris (TC)
Beyond the preview
Go deeper on NCT07312604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07312604.